武田药品（日语：武田薬品／たけだやくひん）是日本一家制药公司，自1781年以「近江屋」药商之名成立至今已有200余年的历史。其于欧洲各国、**、南韩、泰国、新加坡、马来西亚、中国、美国等国皆设有子公司或分公司。

2015年12月16日，阿斯利康制药(AstraZeneca)斥资5.75亿美元收购收购武田药品的核心呼吸药品业务，包括可预防慢性阻塞性肺病(COPD)的药品，在美贩售的药品名为Daliresp，在欧洲则称为Daxas。值得一提的是，Daliresp乃COPD市场首个也是唯一一个选择性磷酸二酯酶-4抑制剂。

Takeda Pharmaceutical Company Ltd(武田薬品工業株式会社,Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company. The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Millennium: The Takeda Oncology Company. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.